skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Intraarterial irradiation with rhenium-188 for inhibition of restenosis after PTCA - strategy and evaluation of Re-188-species for rapid urinary excretion

Journal Article · · Journal of Nuclear Medicine
OSTI ID:563342
; ;  [1]
  1. Oak Ridge National Lab., TN (United States); and others

Estimated costs for coronary restenosis therapy after PTCA are > $ 1 billion (U.S.). Radiation is a simple and effective tool for inhibition of neointimal proliferation an important component of restenosis. We propose use of Re-188 (t{sub {1/2}} 16.9 h, 2.1 MeV {beta}), obtained from decay of W-188 (T{sub {1/2}} 69 d). Our alumina-based W-188/Re-188 generator has a shelf-life of several months and we have developed an on-line tandem cation/anion exchange column system to concentrate to > 18.5 BGq/mL. Estimates for targeted regional dose of 8.4 rad/37 MBq/min/mL, which is > 1,400 cGy for about 370 MBq Re-188 for 5 min. Balloon inflation with Re-188 solutions is a new approach for more uniform vascular dose distribution as an alternative to use of radioactive wires or other linear sources. Rapid urinary excretion kinetics are important in the unlikely event of balloon rupture (<0.1%). We have therefore evaluated relative excretion kinetics of Re-188-perrhenate and -MAG3 in rats; Re-188-perrhenate was obtained from generator elution with 0.9% NaCl and re-188-MAG3 was prepared be reaction of the ligand with Sn(II)-reduced perrhenate. Fischer rats (n=4-5/group) were injected i.v. and urine and feces collected every 2 h for 12 h and then daily for 5 d. Both agents excreted > 90% in urine; biodistribution studies showed low organ uptake with intestines as the major site. Rhenium-188-MAG3 excreted more rapidly (2 h = 59.6{+-}18.5%) then Re-188-MAG3 excreted more rapidly (2 h = 68.3{+-}13.5%) in same model. Both Re-188 species are thus good candidates for balloon inflation. Studies are in progress in a swine model to evaluate the effectiveness of Re-188 for inhibition of restenosis.

DOE Contract Number:
AC05-96OR22464
OSTI ID:
563342
Report Number(s):
CONF-970602-; ISSN 0161-5505; TRN: 97:004028-0014
Journal Information:
Journal of Nuclear Medicine, Vol. 38, Issue Suppl.5; Conference: 44. annual meeting of the Society of Nuclear Medicine, San Antonio, TX (United States), 2-5 Jun 1997; Other Information: PBD: May 1997
Country of Publication:
United States
Language:
English